OUR MISSION

 Integrate artificial intelligence (AI) and multi-omics excellence to create novel Drug/Diagnostic combinations that improve treatment of cancer patients.

 OUR TECHNOLOGY

Our AI-assisted and multi-omics-based  platform enables the identification of modulators and mediated biological functions of the master immune regulator Arylhydrocarbon Receptor (AHR) pan-cancer and in response to cancer immunotherapies.

ABOUT US

cAHRmeleon Bioscience GmbH is an innovative new biotech company founded in December 2021, as a spin-off of the German Cancer Research Center (DKFZ) in Heidelberg, Germany.

Our Solution

Universal AHR-signature

Overcomes cell and ligand type specificity
Validated in 32 cancers
Transferable across multi-omics layers

AI-AHR TECHNOLOGY

We extensively profiled multiple activators of the AHR and the subsequent transcriptional responses across multiple tissues and cancers.

AHR BASE

We possess a broad database of AHR signatures. This database enables us to investigate AHR activity in cancer and autoimmune diseases.

AHR FLOW

Our bioinformatics platform analyses high throughput data for AHR activation and functions from gene expression, proteome and metabolome data.

AHR MARK

Our AI-AHR technology supports patient stratifictaion to therapy and the pediction of patients‘ therapy response.

Our Partners

Contact us for more information

info@cAHRmeleon.com